S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

Hemispherx BioPharma Stock Price, Forecast & Analysis (NYSEAMERICAN:HEB)

$1.96
0.00 (0.00 %)
(As of 09/6/2019)
Today's Range
$1.90
Now: $1.96
$2.06
50-Day Range N/A
52-Week Range
$1.69
Now: $1.96
$14.81
Volume111,364 shs
Average Volume102,599 shs
Market Capitalization$4.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-407-2718516

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees31
Market Cap$4.79 million
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable

Receive HEB News and Ratings via Email

Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter.


Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

When did Hemispherx BioPharma's stock split? How did Hemispherx BioPharma's stock split work?

Hemispherx BioPharma shares reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split.

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter. View Hemispherx BioPharma's Earnings History.

When is Hemispherx BioPharma's next earnings date?

Hemispherx BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for Hemispherx BioPharma.

What price target have analysts set for HEB?

2 brokerages have issued 1 year target prices for Hemispherx BioPharma's shares. Their forecasts range from $6.00 to $8.00. On average, they expect Hemispherx BioPharma's share price to reach $7.00 in the next year. This suggests a possible upside of 257.1% from the stock's current price. View Analyst Price Targets for Hemispherx BioPharma.

What is the consensus analysts' recommendation for Hemispherx BioPharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hemispherx BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hemispherx BioPharma.

Has Hemispherx BioPharma been receiving favorable news coverage?

Press coverage about HEB stock has been trending very negative recently, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hemispherx BioPharma earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Hemispherx BioPharma.

Who are some of Hemispherx BioPharma's key competitors?

What other stocks do shareholders of Hemispherx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), NovaBay Pharmaceuticals (NBY), Biocept (BIOC), Novavax (NVAX), Biopharmx (BPMX), Palatin Technologies (PTN), Goodrich Petroleum (GDPMQ), Celldex Therapeutics (CLDX), CTI BioPharma (CTIC) and Cytori Therapeutics (CYTX).

Who are Hemispherx BioPharma's key executives?

Hemispherx BioPharma's management team includes the folowing people:
  • Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
  • Mr. Adam Pascale, Chief Financial Officer (Age 71)
  • Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
  • Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
  • Ms. Ellen Lintal, Chief Accounting Officer

How do I buy shares of Hemispherx BioPharma?

Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hemispherx BioPharma's stock price today?

One share of HEB stock can currently be purchased for approximately $1.96.

How big of a company is Hemispherx BioPharma?

Hemispherx BioPharma has a market capitalization of $4.79 million. Hemispherx BioPharma employs 31 workers across the globe.View Additional Information About Hemispherx BioPharma.

What is Hemispherx BioPharma's official website?

The official website for Hemispherx BioPharma is http://www.hemispherx.net/.

How can I contact Hemispherx BioPharma?

Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.


MarketBeat Community Rating for Hemispherx BioPharma (NYSEAMERICAN HEB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel